Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: December 2014

8 - Tauopathies


1. N. J. Cairns, E. H. Bigio, I. R. Mackenzie, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007; 114: 5–22.
2. M. D. Weingarten, A. H. Lockwood, S. Y. Hwo, M. W. Kirschner. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975; 72: 1858–62.
3. G. Lee, C. J. Leugers. Tau and tauopathies. Prog Mol Biol Transl Sci 2012; 107: 263–93.
4. M. Goedert, M. G. Spillantini, R. Jakes, D. Rutherford, R. A. Crowther. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989; 3: 519–26.
5. M. G. Spillantini, M. Goedert. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12: 609–22.
6. J. Berriman, L. C. Serpell, K. A. Oberg, et al. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A 2003; 100: 9034–8.
7. N. Sergeant, A. Delacourte, L. Buee. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 2005; 1739: 179–97.
8. K. Iqbal, F. Liu, C. X. Gong, C. Alonso Adel, I. Grundke-Iqbal. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009; 118: 53–69.
9. W. Noble, D. P. Hanger, C. C. Miller, S. Lovestone. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 2013; 4: 83.
10. G. G. Kovacs, G. Botond, H. Budka. Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol 2010; 119: 389–408.
11. B. Ghetti, Z. K. Wszolek, B. F. Boeve, S. Spina, M. Goedert. Frontotemporal dementia and parkinsonism linked to chromosome 17. In: D. W. Dickson, R. O. Weller (eds). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd edn. Chichester, UK: Blackwell Publishing Ltd. 2011: 110–34.
12. M. Cruts, J. Theuns, C. Van Broeckhoven. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012; 33: 1340–4.
13. J. van Swieten, M. G. Spillantini. Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol 2007; 17: 63–73.
14. D. W. Dickson, R. Rademakers, M. L. Hutton. Progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007; 17: 74–82.
15. S. Frank, F. Clavaguera, M. Tolnay. Tauopathy models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 39–53.
16. F. Clavaguera, H. Akatsu, G. Fraser, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 2013; 110: 9535–40.
17. E. Braak, H. Braak, E. M. Mandelkow. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 1994; 87: 554–67.
18. J. Luna-Munoz, L. Chavez-Macias, F. Garcia-Sierra, R. Mena. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease. J Alzheimers Dis 2007; 12: 365–75.
19. M. Pikkarainen, P. Martikainen, I. Alafuzoff. The effect of prolonged fixation time on immunohistochemical staining of common neurodegenerative disease markers. J Neuropathol Exp Neurol 2010; 69: 40–52.
20. R. de Silva, T. Lashley, G. Gibb, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003; 29: 288–302.
21. T. Uchihara, A. Nakamura, K. Shibuya, S. Yagishita. Specific detection of pathological three-repeat tau after pretreatment with potassium permanganate and oxalic acid in PSP/CBD brains. Brain Pathol 2011; 21: 180–8.
22. T. Uchihara. Silver diagnosis in neuropathology: principles, practice and revised interpretation. Acta Neuropathol 2007; 113: 483–99.
23. E. Kuusisto, T. Kauppinen, I. Alafuzoff. Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 2008; 34: 169–80.
24. V. M. Lee, M. Goedert, J. Q. Trojanowski. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121–59.
25. C. M. Wischik, M. Novak, P. C. Edwards, et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 1988; 85: 4884–8.
26. D. W. Dickson. Pick’s disease: a modern approach. Brain Pathol 1998; 8: 339–54.
27. A. Kertesz, L. Hudson, I. R. Mackenzie, D. G. Munoz. The pathology and nosology of primary progressive aphasia. Neurology 1994; 44: 2065–72.
28. C. Russ, S. Lovestone, M. Baker, et al. The extended haplotype of the microtubule associated protein tau gene is not associated with Pick’s disease. Neurosci Lett 2001; 299: 156–8.
29. G. G. Kovacs, A. J. Rozemuller, J. C. van Swieten, et al. Neuropathology of the hippocampus in FTLD-Tau with Pick bodies: a study of the BrainNet Europe Consortium. Neuropathol Appl Neurobiol 2013; 39: 166–78.
30. S. Schraen-Maschke, N. Sergeant, C. M. Dhaenens, et al. Tau as a biomarker of neurodegenerative diseases. Biomark Med 2008; 2: 363–84.
31. K. Arima. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 2006; 26: 475–83.
32. J. C. Steele, J. C. Richardson, J. Olszewski. Progressive Supranuclear Palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–59.
33. D. R. Williams, A. J. Lees. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270–9.
34. D. W. Dickson, Z. Ahmed, A. A. Algom, Y. Tsuboi, K. A. Josephs. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23: 394–400.
35. Z. Ahmed, E. H. Bigio, H. Budka, et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 2013; 126: 537–44.
36. G. Lennox, J. Lowe, K. Morrell, M. Landon, R. J. Mayer. Ubiquitin is a component of neurofibrillary tangles in a variety of neurodegenerative diseases. Neurosci Lett 1988; 94: 211–7.
37. D. R. Williams, J. L. Holton, C. Strand, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 2007; 130: 1566–76.
38. T. Arai, K. Ikeda, H. Akiyama, et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004; 55: 72–9.
39. J. J. Rebeiz, E. H. Kolodny, E. P. Richardson, Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18: 20–33.
40. W. R. Gibb, P. J. Luthert, C. D. Marsden. Corticobasal degeneration. Brain 1989; 112: 1171–92.
41. N. Kouri, J. L. Whitwell, K. A. Josephs, R. Rademakers, D. W. Dickson. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7: 263–72.
42. N. Kouri, K. Oshima, M. Takahashi, et al. Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. Acta Neuropathol 2013; 125: 741–52.
43. D. W. Dickson. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 (Suppl. 2): II6–15.
44. M. Tolnay, A. Probst. Argyrophilic grain disease. Handb Clin Neurol 2008; 89: 553–63.
45. H. Braak, E. Braak. Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett 1987; 76: 124–7.
46. K. Ishihara, S. Araki, N. Ihori, et al. Argyrophilic grain disease presenting with frontotemporal dementia: a neuropsychological and pathological study of an autopsied case with presenile onset. Neuropathology 2005; 25: 165–70.
47. K. Tsuchiya, K. Mitani, T. Arai, et al. Argyrophilic grain disease mimicking temporal Pick’s disease: a clinical, radiological, and pathological study of an autopsy case with a clinical course of 15 years. Acta Neuropathol 2001; 102: 195–9.
48. T. Togo, N. Sahara, S. H. Yen, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 2002; 61: 547–56.
49. Y. Saito, N. N. Ruberu, M. Sawabe, et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63: 911–8.
50. M. Tolnay, F. Clavaguera. Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology 2004; 24: 269–83.
51. T. Ishizawa, L. W. Ko, N. Cookson, et al. Selective neurofibrillary degeneration of the hippocampal CA2 sector is associated with four-repeat tauopathies. J Neuropathol Exp Neurol 2002; 61: 1040–7.
52. I. Ferrer, G. Santpere, F. W. van Leeuwen. Argyrophilic grain disease. Brain 2008; 131: 1416–32.
53. K. A. Josephs, J. L. Whitwell, J. E. Parisi, et al. Argyrophilic grains: a distinct disease or an additive pathology? Neurobiol Aging 2008; 29: 566–73.
54. J. Ulrich, M. Spillantini, M. Goedert, L. Dukas, H. Staehelin. Abundant neurofibrillary tangles without senile plaques in a subset of patients with senile dementia. Neurodegeneration 1992; 1: 257–84.
55. K. A. Jellinger, J. Attems. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol 2007; 113: 107–17.
56. M. E. Murray, N. R. Graff-Radford, O. A. Ross, et al. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011; 10: 785–96.
57. N. J. Janocko, K. A. Brodersen, A. I. Soto-Ortolaza, et al. Neuropathologically defined subtypes of Alzheimer’s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 2012; 124: 681–92.
58. I. Santa-Maria, A. Haggiagi, X. Liu, et al. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 2012; 124: 693–704.
59. G. G. Kovacs, K. Majtenyi, S. Spina, et al. White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 2008; 67: 963–75.
60. C. Schultz, E. Ghebremedhin, K. Del Tredici, U. Rub, H. Braak. High prevalence of thorn-shaped astrocytes in the aged human medial temporal lobe. Neurobiol Aging 2004; 25: 397–405.
61. G. Lace, P. G. Ince, C. Brayne, et al. Mesial temporal astrocyte tau pathology in the MRC-CFAS ageing brain cohort. Dement Geriatr Cogn Disord 2012; 34: 15–24.
62. T. G. Beach, L. Sue, S. Scott, et al. Hippocampal sclerosis dementia with tauopathy. Brain Pathol 2003; 13: 263–78.
63. D. G. Munoz, J. Woulfe, A. Kertesz. Argyrophilic thorny astrocyte clusters in association with Alzheimer’s disease pathology in possible primary progressive aphasia. Acta Neuropathol 2007; 114: 347–57.
64. G. G. Kovacs, K. Molnar, L. Laszlo, et al. A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol 2011; 122: 205–22.
65. G. G. Kovacs, I. Milenkovic, A. Wohrer, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013; 126: 365–84.
66. N. Hishikawa, Y. Hashizume, M. Yoshida, et al. Tuft-shaped astrocytes in Lewy body disease. Acta Neuropathol 2005; 109: 373–80.
67. J. E. Duda, B. I. Giasson, M. E. Mabon, et al. Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 2002; 104: 7–11.
68. A. Zimprich, S. Biskup, P. Leitner, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601–7.
69. A. C. McKee, R. C. Cantu, C. J. Nowinski, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009; 68: 709–35.
70. A. C. McKee, R. A. Stern, C. J. Nowinski, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136: 43–64.
71. M. L. Schmidt, V. Zhukareva, K. L. Newell, V. M. Lee, J. Q. Trojanowski. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer’s disease. Acta Neuropathol 2001; 101: 518–24.
72. K. F. Bieniek, M. E. Murray, N. J. Rutherford, et al. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol 2013; 125: 289–302.
73. A. King, S. Al-Sarraj, C. Troakes, et al. Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. Acta Neuropathol 2013; 125: 303–10.
74. G. G. Kovacs, H. Budka. The spectrum of tau pathology in human prion disease. In: W.-Q. Zou, P. Gambetti (eds). Prions and Diseases. New York: Springer. 2013: 103–19.
75. K. Kosaka. Diffuse neurofibrillary tangles with calcification: a new presenile dementia. J Neurol Neurosurg Psychiatry 1994; 57: 594–6.
76. H. Shibayama, H. Kobayashi, M. Nakagawa, et al. Non-Alzheimer non-Pick dementia with Fahr’s syndrome. Clin Neuropathol 1992; 11: 237–50.
77. C. Habuchi, S. Iritani, H. Sekiguchi, et al. Clinicopathological study of diffuse neurofibrillary tangles with calcification. With special reference to TDP-43 proteinopathy and α-synucleinopathy. J Neurol Sci 2011; 301: 77–85.
78. N. Hashimoto, T. Takeuchi, R. Ishihara, et al. Glial fibrillary tangles in diffuse neurofibrillary tangles with calcification. Acta Neuropathol 2003; 106: 150–6.
79. C. Paisan-Ruiz, A. Li, S. A. Schneider, et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2012; 33: 814–23.
80. R. Distl, S. Treiber-Held, F. Albert, et al. Cholesterol storage and tau pathology in Niemann–Pick type C disease in the brain. J Pathol 2003; 200: 104–11.
81. K. A. Jellinger. Absence of α-synuclein pathology in postencephalitic parkinsonism. Acta Neuropathol 2009; 118: 371–9.
82. V. Buee-Scherrer, L. Buee, B. Leveugle, et al. Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer’s disease and other neurodegenerative disorders. Ann Neurol 1997; 42: 356–9.
83. D. Caparros-Lefebvre, N. Sergeant, A. Lees, et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002; 125: 801–11.
84. K. Oyanagi, T. Hashimoto, M. Yamazaki. Parkinsonism–dementia complex of Guam. In: D. W. Dickson, R. O. Weller (eds). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Chichester, UK: Blackwell Publishing Ltd. 2011: 171–8.
85. J. Miklossy, J. C. Steele, S. Yu, et al. Enduring involvement of tau, β-amyloid, α-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol 2008; 116: 625–37.
86. K. Ikeda, H. Akiyama, H. Kondo, et al. Numerous glial fibrillary tangles in oligodendroglia in cases of subacute sclerosing panencephalitis with neurofibrillary tangles. Neurosci Lett 1995; 194: 133–5.
87. J. Y. Garbern, M. Neumann, J. Q. Trojanowski, et al. A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. Brain 2010; 133: 1391–402.
88. Y. Miki, F. Mori, E. Hori, M. Kaimori, K. Wakabayashi. Hippocampal sclerosis with four-repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. Acta Neuropathol 2009; 117: 713–8.
89. G. G. Kovacs, H. Budka. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol 2010; 29: 271–88.